IR Notice
Closing Announcement of FY2022
CONSILIDATED STATEMENTS OF FINANCIAL POSITION
As of December 31, 2022
(Unit : KRW)
| Account | Amount | Account | Amount |
|---|---|---|---|
| ASSETS | LIABILITIES | ||
| 1. CURRENT ASSETS | 6,457,656,567,077 | 1. CURRENT LIABILITIES | 4,181,541,561,220 |
| Cash and cash equivalents | 890,819,570,657 | Trade and other current payables | 1,761,600,070,367 |
| Short-term financial instruments | 2,168,901,000,000 | Emission liability | 538,848,000 |
| Financial assets at fair value through | 98,505,711,790 | Debentures and borrowings | 1,138,800,019,346 |
| Trade and other receivables | 732,839,221,107 | Contract liabilities | 68,530,178,265 |
| Inventories | 2,375,818,961,320 | Lease liabilities | 142,247,057,483 |
| Contract assets | 87,316,397,189 | Current tax liabilities | 223,298,677,221 |
| Other current financial assets | 48,789,472,350 | Other current liabilities | 846,526,710,538 |
| Other current assets | 54,666,232,664 | ||
| Ⅱ. NON-CURRENT LIABILITIES | 3,416,034,302,109 | ||
| Trade and other payables | 551,366,868,613 | ||
| Debentures and borrowings | 965,090,332,157 | ||
| Deribative liabilities | 22,733,991,336 | ||
| Contract liabilities | 318,360,573,185 | ||
| Lease liabilities | 267,895,530,480 | ||
| Ⅱ. NON-CURRENT ASSETS | 10,124,393,691,409 | Deferrde tax liabilities | 1,214,215,655,517 |
| Long-term financial instruments | 7,335,813,270 | Other non-current liabilities | 76,371,350,821 |
| Trade and other receivables | 4,428,344,378 | ||
| Investments in associate and joint venture | 30,774,605,702 | TOTAL LIABILITIES | 7,597,575,863,329 |
| Property, pant and equipment | 3,416,528,836,940 | ||
| Intangible assets | 5,961,306,684,591 | EQUITY | |
| Right-of-use assets | 454,923,496,204 | Share capial | 177,935,000,000 |
| Defined beneift asset | 29,646,230,762 | Share premium | 5,663,111,352,594 |
| Contract assets | 177,626,602,866 | Accumulated other comprehensive loss | (2,173,393,264) |
| Other non-current financial assets | 322,091,698,923 | Retained earnings | 3,145,601,435,827 |
| Other non-current assets | 3,524,720,204 | ||
| TOTAL EQUITY | 8,984,474,395,157 | ||
| TOTAL ASSETS | 16,582,050,258,486 | TOTAL LIABILITIES AND EQUITY | 16,582,050,258,486 |
March 17, 2023
SAMSUNG BIOLOGICS CO., LTD
president & CEO John Rim
The financial statements present fairly, in all material respects, the financial position the Company as of December 31, 2021 and its financial performance and its cash flows for the years ended December 31, 2020 in accordance with K-IFRS.
Samil PricewaterhouseCoopers CEO Soonsoo Yoon
Closing Announcement of FY2022
SEPARATE STATEMENTS OF FINANCIAL POSITION
As of December 31, 2022
(Unit : KRW)
| Account | Amount | Account | Amount |
|---|---|---|---|
| ASSETS | LIABILITIES | ||
| 1. CURRENT ASSETS | 4,919,357,578,500 | 1. CURRENT LIABILITIES | 2,990,676,467,009 |
| Cash and cash equivalents | 757,945,988,143 | Trade and other current payables | 1,628,734,131,092 |
| Short-term financial instruments | 2,168,901,000,000 | Emission liability | 538,848,000 |
| Financial assets at fair value through | 98,505,711,790 | Debentures and borrowings | 517,997,721,221 |
| Trade and other receivables | 503,997,178,409 | Contract liabilities | 64,204,826,542 |
| Inventories | 1,243,171,975,151 | Lease liabilities | 140,991,867,493 |
| Contract assets | 95,823,666,322 | Current tax liabilities | 187,319,244,039 |
| Other current financial assets | 37,047,599,149 | Other current liabilities | 450,889,828,622 |
| Other current assets | 13,964,459,536 | ||
| Ⅱ. NON-CURRENT LIABILITIES | 1,878,559,194,238 | ||
| Trade and other payables | 542,653,723,715 | ||
| Debentures and borrowings | 765,090,332,157 | ||
| Deribative liabilities | 22,733,991,336 | ||
| Contract liabilities | 225,477,213,506 | ||
| Ⅱ. NON-CURRENT ASSETS | 7,246,481,301,027 | Lease liabilities | 266,232,582,703 |
| Long-term financial instruments | 5,187,000,000 | Other non-current liabilities | 76,371,350,821 |
| Investments in subsidiary, sccociate and joint | 3,308,792,565,514 | TOTAL LIABILITIES | 4,869,235,661,247 |
| Property, pant and equipment | 3,083,545,436,767 | ||
| Intangible assets | 39,436,621,913 | EQUITY | |
| Right-of-use assets | 451,792,929,789 | Share capial | 177,935,000,000 |
| Defined beneift asset | 28,625,478,854 | Share premium | 5,672,425,121,121 |
| Contract assets | 208,515,931,997 | Accumulated other comprehensive loss | (6,726,079,112) |
| Deferred tax assets | 82,270,164,199 | Retained earnings | 1,452,969,176,271 |
| Other non-current financial assets | 25,954,612,332 | ||
| Other non-current assets | 1,725,557,715 | TOTAL EQUITY | 7,296,603,218,280 |
| TOTAL ASSETS | 12,165,838,879,527 | TOTAL LIABILITIES AND EQUITY | 12,165,838,879,527 |
March 17, 2023
SAMSUNG BIOLOGICS CO., LTD
president & CEO John Rim
The financial statements present fairly, in all material respects, the financial position the Company as of December 31, 2021 and its financial performance and its cash flows for the years ended December 31, 2020 in accordance with K-IFRS.
Samil PricewaterhouseCoopers CEO Soonsoo Yoon
Closing Announcement of FY2022
CONSILIDATED STATEMENTS OF FINANCIAL POSITION
As of December 31, 2022
(Unit : KRW)
| Account | Amount | Account | Amount |
|---|---|---|---|
| ASSETS | LIABILITIES | ||
| 1. CURRENT ASSETS | 6,457,656,567,077 | 1. CURRENT LIABILITIES | 4,181,541,561,220 |
| Cash and cash equivalents | 890,819,570,657 | Trade and other current payables | 1,761,600,070,367 |
| Short-term financial instruments | 2,168,901,000,000 | Emission liability | 538,848,000 |
| Financial assets at fair value through | 98,505,711,790 | Debentures and borrowings | 1,138,800,019,346 |
| Trade and other receivables | 732,839,221,107 | Contract liabilities | 68,530,178,265 |
| Inventories | 2,375,818,961,320 | Lease liabilities | 142,247,057,483 |
| Contract assets | 87,316,397,189 | Current tax liabilities | 223,298,677,221 |
| Other current financial assets | 48,789,472,350 | Other current liabilities | 846,526,710,538 |
| Other current assets | 54,666,232,664 | ||
| Ⅱ. NON-CURRENT LIABILITIES | 3,416,034,302,109 | ||
| Trade and other payables | 551,366,868,613 | ||
| Debentures and borrowings | 965,090,332,157 | ||
| Deribative liabilities | 22,733,991,336 | ||
| Contract liabilities | 318,360,573,185 | ||
| Lease liabilities | 267,895,530,480 | ||
| Ⅱ. NON-CURRENT ASSETS | 10,124,393,691,409 | Deferrde tax liabilities | 1,214,215,655,517 |
| Long-term financial instruments | 7,335,813,270 | Other non-current liabilities | 76,371,350,821 |
| Trade and other receivables | 4,428,344,378 | ||
| Investments in associate and joint venture | 30,774,605,702 | TOTAL LIABILITIES | 7,597,575,863,329 |
| Property, pant and equipment | 3,416,528,836,940 | ||
| Intangible assets | 5,961,306,684,591 | EQUITY | |
| Right-of-use assets | 454,923,496,204 | Share capial | 177,935,000,000 |
| Defined beneift asset | 29,646,230,762 | Share premium | 5,663,111,352,594 |
| Contract assets | 177,626,602,866 | Accumulated other comprehensive loss | (2,173,393,264) |
| Other non-current financial assets | 322,091,698,923 | Retained earnings | 3,145,601,435,827 |
| Other non-current assets | 3,524,720,204 | ||
| TOTAL EQUITY | 8,984,474,395,157 | ||
| TOTAL ASSETS | 16,582,050,258,486 | TOTAL LIABILITIES AND EQUITY | 16,582,050,258,486 |
March 17, 2023
SAMSUNG BIOLOGICS CO., LTD
president & CEO John Rim
The financial statements present fairly, in all material respects, the financial position the Company as of December 31, 2021 and its financial performance and its cash flows for the years ended December 31, 2020 in accordance with K-IFRS.
Samil PricewaterhouseCoopers CEO Soonsoo Yoon
Closing Announcement of FY2022
SEPARATE STATEMENTS OF FINANCIAL POSITION
As of December 31, 2022
(Unit : KRW)
| Account | Amount | Account | Amount |
|---|---|---|---|
| ASSETS | LIABILITIES | ||
| 1. CURRENT ASSETS | 4,919,357,578,500 | 1. CURRENT LIABILITIES | 2,990,676,467,009 |
| Cash and cash equivalents | 757,945,988,143 | Trade and other current payables | 1,628,734,131,092 |
| Short-term financial instruments | 2,168,901,000,000 | Emission liability | 538,848,000 |
| Financial assets at fair value through | 98,505,711,790 | Debentures and borrowings | 517,997,721,221 |
| Trade and other receivables | 503,997,178,409 | Contract liabilities | 64,204,826,542 |
| Inventories | 1,243,171,975,151 | Lease liabilities | 140,991,867,493 |
| Contract assets | 95,823,666,322 | Current tax liabilities | 187,319,244,039 |
| Other current financial assets | 37,047,599,149 | Other current liabilities | 450,889,828,622 |
| Other current assets | 13,964,459,536 | ||
| Ⅱ. NON-CURRENT LIABILITIES | 1,878,559,194,238 | ||
| Trade and other payables | 542,653,723,715 | ||
| Debentures and borrowings | 765,090,332,157 | ||
| Deribative liabilities | 22,733,991,336 | ||
| Contract liabilities | 225,477,213,506 | ||
| Ⅱ. NON-CURRENT ASSETS | 7,246,481,301,027 | Lease liabilities | 266,232,582,703 |
| Long-term financial instruments | 5,187,000,000 | Other non-current liabilities | 76,371,350,821 |
| Investments in subsidiary, sccociate and joint | 3,308,792,565,514 | TOTAL LIABILITIES | 4,869,235,661,247 |
| Property, pant and equipment | 3,083,545,436,767 | ||
| Intangible assets | 39,436,621,913 | EQUITY | |
| Right-of-use assets | 451,792,929,789 | Share capial | 177,935,000,000 |
| Defined beneift asset | 28,625,478,854 | Share premium | 5,672,425,121,121 |
| Contract assets | 208,515,931,997 | Accumulated other comprehensive loss | (6,726,079,112) |
| Deferred tax assets | 82,270,164,199 | Retained earnings | 1,452,969,176,271 |
| Other non-current financial assets | 25,954,612,332 | ||
| Other non-current assets | 1,725,557,715 | TOTAL EQUITY | 7,296,603,218,280 |
| TOTAL ASSETS | 12,165,838,879,527 | TOTAL LIABILITIES AND EQUITY | 12,165,838,879,527 |
March 17, 2023
SAMSUNG BIOLOGICS CO., LTD
president & CEO John Rim
The financial statements present fairly, in all material respects, the financial position the Company as of December 31, 2021 and its financial performance and its cash flows for the years ended December 31, 2020 in accordance with K-IFRS.
Samil PricewaterhouseCoopers CEO Soonsoo Yoon